Pulmonx Co. (NASDAQ:LUNG) Shares Sold by Pura Vida Investments LLC

Pura Vida Investments LLC trimmed its holdings in Pulmonx Co. (NASDAQ:LUNG) by 24.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 387,200 shares of the company’s stock after selling 122,575 shares during the quarter. Pulmonx comprises about 8.3% of Pura Vida Investments LLC’s portfolio, making the stock its 4th biggest position. Pura Vida Investments LLC owned approximately 0.98% of Pulmonx worth $2,629,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. 272 Capital LP bought a new position in Pulmonx in the third quarter worth approximately $25,000. R Squared Ltd bought a new position in shares of Pulmonx in the 4th quarter worth $46,000. SG Americas Securities LLC grew its position in Pulmonx by 27.0% in the 4th quarter. SG Americas Securities LLC now owns 15,555 shares of the company’s stock valued at $106,000 after purchasing an additional 3,310 shares during the period. American Century Companies Inc. increased its stake in Pulmonx by 8.8% during the 4th quarter. American Century Companies Inc. now owns 34,738 shares of the company’s stock valued at $236,000 after purchasing an additional 2,810 shares in the last quarter. Finally, Rhumbline Advisers increased its stake in Pulmonx by 4.9% during the 4th quarter. Rhumbline Advisers now owns 53,503 shares of the company’s stock valued at $363,000 after purchasing an additional 2,488 shares in the last quarter. Institutional investors and hedge funds own 91.04% of the company’s stock.

Analyst Upgrades and Downgrades

LUNG has been the subject of a number of analyst reports. Wells Fargo & Company cut their price target on Pulmonx from $10.00 to $8.00 and set an “equal weight” rating for the company in a research note on Wednesday, December 11th. Morgan Stanley assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They set an “equal weight” rating on the stock. D. Boral Capital started coverage on shares of Pulmonx in a report on Monday, March 10th. They issued a “buy” rating and a $17.00 target price for the company. Citigroup assumed coverage on shares of Pulmonx in a report on Monday, March 10th. They set a “buy” rating on the stock. Finally, Jefferies Financial Group initiated coverage on shares of Pulmonx in a research report on Monday, March 10th. They issued a “buy” rating for the company. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $13.36.

Pulmonx Price Performance

Shares of NASDAQ:LUNG opened at $6.82 on Friday. The company’s fifty day moving average is $7.17 and its 200 day moving average is $6.95. The company has a quick ratio of 6.77, a current ratio of 7.70 and a debt-to-equity ratio of 0.40. Pulmonx Co. has a 52 week low of $5.46 and a 52 week high of $10.01. The stock has a market cap of $271.41 million, a PE ratio of -4.74 and a beta of 0.50.

Pulmonx (NASDAQ:LUNG) last released its quarterly earnings data on Wednesday, February 19th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.45) by $0.12. The firm had revenue of $23.77 million for the quarter, compared to analysts’ expectations of $22.29 million. Pulmonx had a negative net margin of 67.31% and a negative return on equity of 55.36%. Research analysts anticipate that Pulmonx Co. will post -1.55 earnings per share for the current year.

Insider Transactions at Pulmonx

In other news, Director Glendon E. French III sold 20,000 shares of the stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $7.85, for a total transaction of $157,000.00. Following the sale, the director now owns 991,974 shares in the company, valued at $7,786,995.90. This represents a 1.98 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, General Counsel David Aaron Lehman sold 22,355 shares of the company’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $7.65, for a total transaction of $171,015.75. Following the transaction, the general counsel now owns 175,496 shares in the company, valued at $1,342,544.40. This represents a 11.30 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 147,986 shares of company stock valued at $1,143,673. Company insiders own 5.70% of the company’s stock.

About Pulmonx

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation.